Adamas Pharmaceuticals (ADMS)
NASDAQ:ADMS

Adamas Pharmaceuticals Stock Analysis & Ratings

Adamas Pharmaceuticals Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Adamas Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

ADMS

ADMS Stock Stats

Previous Close$8.22
Open$0
Bid0 x 0
Ask0 x 0
Today’s Range$0 - $0
52-Week Range$4.02 - $9.15
VolumeN/A
Average Volume951.98K
Market Cap$376.37M
Beta2.81
P/E Ratio-4.8
EPS-1.70

Company Description

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Neil F. McFarlane
Employees
138
Website
http://www.adamaspharma.com
ISIN
US00548A1060
Address
1900 Powell Street, Emeryville, CA, 94608, US

Financials

Currently, no data available
Please return soon. This page is being updated.

P/E Ratio Range

Currently, no data available
Please return soon. This page is being updated.
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

ADMS FAQ

What was Adamas Pharmaceuticals’s price range in the past 12 months?
Adamas Pharmaceuticals lowest stock price was $4.02 and its highest was $9.15 in the past 12 months.
    What is Adamas Pharmaceuticals’s market cap?
    Adamas Pharmaceuticals’s market cap is $376.37M.
      What is Adamas Pharmaceuticals’s price target?
      The average price target for Adamas Pharmaceuticals is $8.40. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $9.10 ,the lowest forecast is $8.00. The average price target represents 2.19% Increase from the current price of $8.22.
        What do analysts say about Adamas Pharmaceuticals?
        Adamas Pharmaceuticals’s analyst rating consensus is a ‘Hold. This is based on the ratings of 7 Wall Streets Analysts.
          When is Adamas Pharmaceuticals’s upcoming earnings report date?
          The company’s upcoming earnings report date is not yet available.
          How were Adamas Pharmaceuticals’s earnings last quarter?
          Currently, no data Available
          Is Adamas Pharmaceuticals overvalued?
          According to Wall Street analysts Adamas Pharmaceuticals’s price is currently Undervalued.
            Does Adamas Pharmaceuticals pay dividends?
            Adamas Pharmaceuticals does not currently pay dividends.
            What is Adamas Pharmaceuticals’s EPS estimate?
            Adamas Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Adamas Pharmaceuticals have?
            Adamas Pharmaceuticals has 45,790,000 shares outstanding.
              What happened to Adamas Pharmaceuticals’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Adamas Pharmaceuticals?
              Among the largest hedge funds holding Adamas Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Adamas Pharmaceuticals’s shares valued at N/A.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis